Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07029412
PHASE2

Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)

Sponsor: MBX Biosciences

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the preliminary efficacy of single SC administration of MBX 1416 at different dose levels in patients with PBH

Official title: A Phase 2a, Open-label, Exploratory Study to Evaluate Preliminary Efficacy of Subcutaneous MBX 1416 in Patients With Postbariatric Hypoglycemia (The STEADI Study)

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2025-08-26

Completion Date

2026-01-26

Last Updated

2025-12-17

Healthy Volunteers

No

Interventions

DRUG

MBX 1416 (INN imapextide)

A single subcutaneous injection of MBX 1416 at a low dose and a high dose approximately 2 weeks apart.

Locations (4)

MBX Biosciences Investigational Site

Aurora, Colorado, United States

MBX Biosciences Investigational Site

Morehead City, North Carolina, United States

MBX Biosciences Investigational Site

Knoxville, Tennessee, United States

MBX Biosciences Investigational Site

San Antonio, Texas, United States